<DOC>
	<DOCNO>NCT00152490</DOCNO>
	<brief_summary>A 26 week study examine efficacy , safety pharmacokinetics CDP870 Crohn 's disease</brief_summary>
	<brief_title>A Study Test Effect CDP870 Treatment Crohn 's Disease Over 26 Weeks , Comparing CDP870 Dummy Drug ( Placebo )</brief_title>
	<detailed_description>Receiving immunosuppressant ( azathioprine/6-MP/methotrexate ) Week 0 . 604 patient enrolled 1006 patient screen ( allow 25 % screen failure screen Week 0 expect presentation Screening 60 % patient CRP &lt; 10 mg/L 40 % patient CRP ≥ 10 mg/L ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Definitive diagnosis Crohn 's disease confirm ( least 3 month prior study entry ) either radiological , endoscopic histological evidence , affect terminal ileum ( L1 ) , colon ( L2 ) ileocolon ( L3* . *Vienna Classification ( 1998 ) Active Crohn 's disease ( ≥ 220 ≤ 450 ) score 7 day prior first dose study drug . Male female age 18 year screen . Patients meet concomitant medication criterion protocol specify table . For drug take screening , patient able remain stable dose throughout duration study , although steroid may taper start Weeks 8 12 . Crohn 's Disease Related Fistula abscess present screening . Stricturing type disease symptom sign noninflammatory mechanical obstruction bowel perforation last 3 month . Short bowel syndrome . Functional colostomy ileostomy ( note : patient temporary stoma past , reverse , eligible enter study ) . Positive stool laboratory result enteric pathogen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Crohn 's disease , CDP870 , CDAI , clinical response , remission ,</keyword>
	<keyword>Certolizumab Pegol , Cimzia</keyword>
</DOC>